Sign inJoin waitlistJoin the waitlist

Angela Steineck

Assistant Professor · Medical College of Wisconsin Affiliated Hospitals, Inc

Credentials: · · · · ·

History

Medical College of Wisconsin Affiliated Hospitals, Inc
Present

Pediatric Hematology/Oncology
University of Washington School of Medicine
2016–2019
Pediatrics
Stanford University School of Medicine
2013–2016
2020, University of Washington, MS
Medical College of Wisconsin
2009–2013

Research

Trends in End-of-Life Care in Pediatric Hematology, Oncology, and Stem Cell Transplant Patients
Pediatric Blood & Cancer · 2016 · 61 citations
A novel combined resilience and advance care planning intervention for adolescents and young adults with advanced cancer: A feasibility and acceptability cohort study
Cancer · 2021 · 32 citations
A Psychosocial Intervention's Impact on Quality of Life in AYAs with Cancer: A Post Hoc Analysis from the Promoting Resilience in Stress Management (PRISM) Randomized Controlled…
Children · 2019 · First of 6 authors · 29 citations

Abby Rosenberg
15 papers
Jennifer Knight
5 papers
Molly Taylor
5 papers · 4 as a fellow
Allison Leahy
3 papers
Corinne Summers
3 papers
Deena Levine
3 papers
Sara Silbert
3 papers
Adam Lamble
2 papers
Anurekha Hall
2 papers
Clare Twist
2 papers
Deepa Bhojwani
2 papers
Elizabeth McCauley
2 papers

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2018–2030